the concept that tumor development relies on the activation of oncogenes and the loss of function of tumor suppressor genes is still prevailing, but this binary view needs revising as genes associated with DNA
To characterize the involvement of the BRCA1 and TP53 tumor suppressor genes and of the KRAS2 protooncogene in gynecologic cancer, mutation analysis of these genes was conducted in pelvic tumors of 85 patients that included 49 epithelial ovarian carcinoma cases. The 85 pelvic tumors contained 5 ...
First and foremost,TP53mutations result in a loss of p53’s tumor suppressor function (loss of function, LOF), which is sufficient to initiate tumorigenesis in humans and mice6,7. In some cases, secondary alterations such as aneuploidy can lead to accumulation of missense mutant proteins that g...
· 导异常细胞衰老及凋亡,参与DNA修复等机制来 预防和抑制异常细胞的产生[3].随着对仅发生TP53 突变的NSCLC患者的深入研究,越来越多的研究 者将目光投向了TP53的共存突变,如表皮生长因 子受体(epidermal growth factor receptor,EGFR)或 鼠类肉瘤病毒癌基因(Kirsten rat sarcoma viral oncogene,KRAS)与TP53的共存突变...
The mutational landscape of TP53, a tumor suppressor mutated in about half of all cancers, includes over 2,000 known missense mutations. To fully leverage TP53 mutation status for personalized medicine, a thorough understanding of the functional diversit
The difference may be due to a well-differentiated cell subpopulation and/or the presence of factors that increased the differentiation of ZJU-0327, ZJU-0725, and ZJU-1127 cells during the establishment of these cell lines. Expression of the proto-oncogene and receptor tyrosine kinase EGFR was ...
The p53 proto-oncogene can act as a suppressor of transformation. Cell. 1989;57(7):1083–1093. 34. Scopinaro MJ, Casak SJ. Paediatric oncology in Argentina: medical and ethical issues. Lancet Oncol. 2002;3(2):111–117. 35. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, ...
In addition, reactivating p53 in tumors with p53 inactivation can induce tumor stabilization or regression [7, 8]. Therefore, drugs targeting p53 loss of function could represent a promising approach for HCC treatment. MET (c-MET) is a protooncogene that encodes the hepatocyte growth factor (...
Want to thank TFD for its existence?Tell a friend about us, add a link to this page, or visitthe webmaster's page for free fun content. Link to this page: Facebook Twitter Full browser? Complete English Grammar Rules is now available in paperback and eBook formats. ...
A mutation screening of oncogenes, tumor suppressor gene TP53 and nuclear encoded mitochondrial complex I genes in oncocytic thyroid tumors. BMC Cancer. 2015; 15:157.